Prime minister


More than 160,000 Australians per year will benefit from the Australian
Government’s decision to provide subsidised access to 48 medicines,
including treatments for serious heart conditions including heart failure in
infants and children, rare but serious infections like tuberculosis, and
These listings include drugs that were deferred in February and new drugs
recently considered and approved for listing by Cabinet.
When some listings on the Pharmaceutical Benefits Scheme (PBS) were
deferred in February, the Government said it would reconsider these drugs
when fiscal circumstances allowed.
Budget savings created by price reductions arising from more
competitively priced medicines, as well as a number of recent
Pharmaceutical Benefits Advisory Committee (PBAC) recommendations,
mean that it is now possible to list these medicines.
These PBS listings come as the Government also agreed with consume r
and industry groups to improve the certainty around the PBS listing
As part of our commitment with the Consumers Health Forum, Generic
Medicines Industry Association and Medicines Australia:
The Government, industry and consumer groups agreed to work together to discuss ways to manage deferrals into the future. They also agreed to work together on further savings for the 2012 - 13 Budget and other savings following the expiry of the memorandum of understanding between industry and Government. The Government committed to not defer any drugs that cost under $10 million a year for the coming year, while it works with all parties to achieve longer-term PBS sustainability. Industry has also agreed to legislative amendments to complete price disclosure reforms, which will help to end anomalies in the current pricing system. This builds on the Gillard Government’s strong track record of working productively with industry and consumer groups to deliver a sustainable PBS that provides Australians with access to affordable medicines. New listings on the PBS and price changes

Most listings will take effect from 1 December 2011, subject to final listing
arrangements being met by the suppliers of these medicines and will
paliperadone palmitate (Invega Sustenna®) - for the treatment of oxycodone/naloxone (Targin®) - for the treatment of severe cancer budesonide with eformoterol (Symbicort®) - for the treatment of lung botulinum toxin type A (Botox®) extension - for the treatment of dalteparin sodium (Fragmin®) - for the treatment of blood clots in nafarelin (Synarel®) - for the treatment of patients undergoing in- alendronate (Fosamax®) - for the treatment of osteoporosis asenapine (Saphris®)- for the treatment of bipolar 1 disorder and bortezomib (Velcade®)- for the treatment of multiple myeloma in patients with severe acute renal failure capecitabine (Xeloda®)- for the treatment of patients with advanced darunavir (Prezista®)- for the treatment of HIV infection denosumab (Xgeva®)- for the treatment of bone metastases from breast cancer and hormone-resistant prostate cancer losartan (Cozavan®) - for the treatment of hypertension magnesium aspartate (Mag-Sup®) - for the treatment of hypomagnesaemia and chronic renal disease in Aboriginal and Torres Strait Islander persons rituximab (Mabthera®)- a high cost medicine for the treatment of a specific form of chronic lymphocytic leukaemia. The Government has also agreed to increase the price of 23 medicines currently listed on the PBS including: digoxin oral solution (Lanoxin®) - for the treatment of serious heart conditions including heart failure in infants and children dothiepin (Dothep®) - for the treatment of depression oxprenolol (Corbeton®) - for the treatment of high blood pressure, rifampicin (Rimycin®) - for the treatment of rare but serious infections including tuberculosis and as a prophylaxis for close contacts of patients with meningococcal disease ritonavir (Norvir®) - for the treatment of HIV infection erythromycin lactobionate (Erythrocin-IV®) and erythromycin ethyl succinate (E-Mycin 200®, E.E.S. 200®, E-Mycin 400® and E.E.S. Granules®) - for the treatment of bacterial infections acarbose (Glucobay®) - for the treatment of diabetes Glucose indicator - urine (Diastix®) – used by diabetes patients Hexamine hippurate (Hiprex®) - for the treatment of bacterial Pancreatic extract (Creon 10,000®, Creon 25,000® and Creon 40,000®) - for the treatment of enzyme deficiency in children and adults Sucralfate (Ulcyte® and Carafate®) - for the treatment of peptic

The Government has also considered the advice of the PBAC of March
2011 with respect to the medicine dabigatran (Pradaxa®), which will cost
the budget up to
$1 billion over the forward estimates. PBAC advised that, based on the
results of the pivotal clinical trial, Pradaxa represents a safe, efficacious
and cost effective therapy for some ‘at risk’ stroke patients.
However, PBAC also raised some important questions about listing
Pradaxa on the PBS that require further consideration. Importantly, PBAC
advised the Government that the benefit of Pradaxa® observed in a clinical
trial context may or may not be reflected wholly in the Australian
population which may lead to this medicine being over prescribed without
an adequate education campaign for doctors, pharmacists and patients.
Following this advice, the Government will commission Emeritus Professor
Lloyd Sansom AO, the former Chair of PBAC, to inform the Government
on options for improving the health outcomes of patients treated with
anticoagulation therapies, including optimising the use of currently
available treatments in Australia as well as the future role of newer
therapies for the treatment of atrial fibrillation, such as Pradaxa®.
The terms of the commitment made between the Australian Government,
the Consumers Health Forum, Generic Medicines Industry Association and
Medicines Australia is available from

For media inquires about specific drugs listed on the PBS, please
call: (02) 6289 7400
PRESS OFFICE (02) 6277 7744




STATE OF THE EVIDENCE What is the Connection Between Chemicals and Breast Cancer? Breast cancer now strikes more women than any other type of cancer, the result of adramatic increase that has taken place in the industrialized world during the past halfcentury. Whereas one in 22 women were diagnosed with breast cancer in the 1940s, nowthe incidence is one in eight. Of all women who die of

Calm campaign has to pull helpline

Date: 24/1/08 Hyndburn becomes new ‘CALMzone’ The cream of UK Asian hip-hop and the regions hottest live bands are coming to Accrington to launch a brand new Initiative in the region with the support of East Lancs PCT . Metz & Trix, Surinder Rattan and L.H.One are all playing in a free gig at the Accrington Town Hall ballroom on 29th Jan to mark the launch of the Hy

Copyright ©2010-2018 Medical Science